Delivery Order SPE2DB22D2211-SPE2DB25FRZGL
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $5,587.40 to AmerisourceBergen Drug Corp for 200-unit vials of Xeomin, a botulinum toxin product used for medical and therapeutic purposes. This firm fixed-price delivery order, issued on September 15, 2025, with an ultimate completion date of October 6, 2025, represents a non-set-aside competitive award to the prime contractor. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency (DLA) awarded a $30,878.12 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 200-unit vials of Xeomin, a botulinum toxin product used for therapeutic and cosmetic medical applications. This non-set-aside contract, issued on September 17, 2025, with completion targeted for October 8, 2025, represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX). The IDC, valued at...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for 200-unit vials of Xeomin, a botulinum toxin product commonly used for therapeutic and cosmetic applications in military and veteran healthcare settings. This firm fixed-price delivery order, valued at $2,514.33, was competitively awarded without set-aside provisions and is scheduled for completion by September 17, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as the performance...
- The Defense Logistics Agency awarded a $1,396.85 delivery order to AmerisourceBergen Drug Corp for 100-unit vials of Xeomin, a botulinum toxin product used for therapeutic and cosmetic medical applications. This firm fixed price delivery order, issued on July 24, 2025, with an ultimate completion date of August 14, 2025, will be performed at the contractor's Corporate Office location in Conshohocken, Pennsylvania. The award was made through open competition with no set-aside designation. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for 200-unit vials of Xeomin, a botulinum toxin product used for therapeutic and cosmetic medical applications. This firm fixed-price delivery order, issued on August 20, 2025, carries a ceiling value of $13,968.50 and is scheduled for completion by September 11, 2025. The contract was competitively awarded without a set-aside designation, with performance taking place at AmerisourceBergen's facility in...
- The Defense Logistics Agency awarded a $16,762.20 firm fixed price delivery order to AmerisourceBergen Drug Corp for 100-unit vials of Xeomin, a botulinum toxin product used for therapeutic and cosmetic medical applications. The contract was competitively awarded without set-aside designation and is scheduled for completion by May 16, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical procurement, particularly...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for 200-unit vials of Xeomin, a botulinum toxin product used for medical and therapeutic purposes, with a ceiling value of $11,174.80. The contract, awarded on June 26, 2025, with an ultimate completion date of July 18, 2025, is structured as a firm fixed-price delivery order with no set-aside designation. Performance will take place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania....
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for 100-unit vials of Xeomin, a botulinum toxin product used for medical and therapeutic purposes, valued at $8,381.10. Issued on August 18, 2025, with an ultimate completion date of September 9, 2025, this firm fixed-price delivery order represents a competitive award with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a...
- The Defense Logistics Agency awarded a delivery order valued at $1,676.22 to AmerisourceBergen Drug Corp for 100-unit vials of Xeomin, a botulinum toxin product used for therapeutic and cosmetic medical applications. This firm fixed-price delivery order, issued on March 18, 2025, is scheduled for completion by April 8, 2025, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The award was competitively procured with no set-aside designation,...
- The Defense Logistics Agency awarded a delivery order valued at $2,234.96 to AmerisourceBergen Drug Corp for 100-unit vials of Xeomin, a botulinum toxin product used in medical and therapeutic applications. This firm fixed-price delivery order, issued on September 5, 2025, with completion targeted for September 26, 2025, is being fulfilled from the vendor's location in Conshohocken, Pennsylvania. The award utilizes no set-aside designation, indicating it was competitively awarded under open...
- SPE2DB22D2211Indefinite Delivery Contract
- SPE2DB22D2211-SPE2DB25FRZGLDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $5,587.40 to AmerisourceBergen Drug Corp for 100-unit vials of Xeomin, a botulinum toxin product used for therapeutic and cosmetic medical applications. The contract, awarded on June 17, 2025, is a firm fixed-price delivery order with a completion date of July 10, 2025, and involves no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems. This delivery order is issued under AmerisourceBergen Drug Corp's Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (contract number SPE2DX), which is valued at $999,999,999.00 and extends through December 2026. The parent IDC serves as a comprehensive global pharmaceutical support vehicle enabling the contractor to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide, including the Defense Health Agency and U.S. Coast Guard. The delivery order reflects the company's established role within the DLA's pharmaceutical supply chain and demonstrates its capability to fulfill specialized medical procurement requirements on a competitive basis.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.6k | 6/17/25 |